United States· US:76336-455_47d0c075-05db-df45-e063-6294a90a4e12

Metopirone

A metyrapone product containing metyrapone, registered in United States by HRA Pharma Rare Diseases. The same ATC class is registered in 14 of our 19 countries.

ATC V04CD01US label

Checked against FDA National Drug Code directory (United States) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about metyraponeAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Metyrapone is registered in 14 of 19 countries.

Countries holding a registration under ATC V04CD01 (metyrapone), each read from that country’s own register.

This record: United States, from FDA National Drug Code directory (United States)
8 of them publish a price we can compare per daily dose

Search metyrapone products by name

Metyrapone · ATC V04CD01

14 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of metyrapone costs, country by country.

Normalised to the WHO defined daily dose (3 g), so markets compare like for like.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Metyrapone · price per daily dose (3 g)

USD · FX 28 Sept 2026

CH Switzerland$91.87
FR France$70.58

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)

Active substance: METYRAPONE
Manufacturer: HRA Pharma Rare Diseases
Country: United States (US)
ATC code: V04CD01
ATC class: Metyrapone
Defined daily dose: 3 g, O
Reimbursed: Not published by this register
Source register: FDA National Drug Code directory (United States)
Last checked: September 27, 2026

Packs & prices · 2

ndc11
7633645518
18 CAPSULE, GELATIN COATED in 1 BOTTLE (76336-455-18)
ndc11
76336-455-18

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

14 interactions on record for metyrapone.

Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check metyrapone against other medicines How interaction checks work

Metyrapone · interactions on record

14 records

14 moderate

Most severe, free to view

CyproheptadinA15AA01moderate
EstradiolD11AX34moderate
Levonorgestrel and ethinylestradiolG03AA07moderate
Desogestrel and ethinylestradiolG03AA09moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Metyrapone in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metyrapone products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

Austria · Metycor
Bulgaria · Metopirone
Czechia · Metopirone
Germany · Metopiron
Denmark · Metopirone
Estonia · Cormeto
Spain · Metopirone
Finland · Metopirone
France · Metyrapone Esteve
Greece · Metopirone
Croatia · Metopirone
Hungary · Cormeto
Ireland · Metopirone
Italy · Cormeto
Lithuania · Cormeto
Latvia · Metopirone
Netherlands · Metopirone
Norway · Metycor
Poland · Metopirone
Portugal · Metopirone Esteve Pharmaceuticals
Romania · Metopirone
Sweden · Metopirone
Slovenia · Metycor
Slovakia · Metopirone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/2a39e665-c728-433b-bab9-51ad60f6da51
GET /v1/drugs/2a39e665-c728-433b-bab9-51ad60f6da51?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "250",
  "substance": "METYRAPONE",
  "productndc": "76336-455",
  "dosage_form": "CAPSULE, GELATIN COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA012911",
  "marketing_category": "NDA"
}

API reference MCP server Plans

See everything about metyrapone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console